Evidence map›Paper›PMID 22523381›Full record

ArticleExperimental physiology2012

Muscle cyclo-oxygenase-2 pathway contributes to the exaggerated muscle mechanoreflex in rats with congestive heart failure.

Ariel Morales, Wei Gao, Jian Lu, Jihong Xing, Jianhua Li

Open access · bronzeAbstract read
In one paragraph

Article in Experimental physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Thromboxane APhysiological reports · 2021
    Article
  10. Article
  11. Review
  12. No effect of endoperoxide 4 or thromboxane AExperimental physiology · 2020
    Article
  13. Thromboxane AAmerican journal of physiology. Heart and circulatory physiology · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Muscle mechanoreflex activation via passive calf stretch causes renal vasoconstriction in healthy humans.American journal of physiology. Regulatory, integrative and comparative physiology · 2017
    Article
  18. ASIC3 contributes to the blunted muscle metaboreflex in heart failure.Medicine and science in sports and exercise · 2015
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ariel MoralesHeart & Vascular Institute, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Wei Gao
Jian Lu
Jihong Xing
Jianhua Li
Penn State Milton S. Hershey Medical Center · USPennsylvania State University · US

Funding

Interstitial Norepinephrine and Heart FailureR01HL075533 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LI, JIANHUA · 2004 to 2007
$1.1M
Autonomic Regulation of Muscle Reflex in Heart FailureR01HL078866 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LI, JIANHUA · 2005 to 2008
$993k
Sympathetic Nervous System and Heart Failure-Role of Primary Afferent NeuronsR01HL090720 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI LI, JIANHUA · 2009 to 2010
$776k
NHLBI NIH HHS R01 HL075533NHLBI NIH HHS R01 HL078866NHLBI NIH HHS R01 HL090720
6 · The paper itself

Abstract

Cyclo-oxygenase (COX) enzymes are responsible for the formation from arachidonic acid of prostaglandins, among other metabolites. Prior studies have suggested that inhibition of the COX pathway attenuates the responses of sympathetic nerve activity and blood pressure during static muscle contraction. Static muscle contraction activates the exercise pressor reflex, which in turn increases sympathetic nerve activity and blood pressure. Also, COX products contribute to exaggeration of the exercise pressor reflex in heart failure (HF). This dysfunction of the exercise pressor reflex has previously been shown to be mediated primarily by muscle mechanoreflex overactivity. It is well known that COX-1 and COX-2 are two isoforms of the enzyme that lead to formation of these important biological mediators involved in the muscle reflex. Thus, in the present study, we determined whether the COX-1 and/or COX-2 pathway contribute(s) to the augmented mechanoreflex activity in HF. First, Western blot analysis was employed to examine protein expression of COX-1 and COX-2 in skeletal muscle tissue of control rats and rats with HF induced by myocardial infarction. Our data show that there is no significant difference in COX-1 expression in both experimental groups. However, COX-2 displays significant overexpression in rats with HF compared with control rats (optical density 1.06 ± 0.05 in control and 1.6 ± 0.05 in HF, P < 0.05 versus control). Second, the mechanoreflex was evoked by passive tendon stretch, and the reflex sympathetic and pressor responses to muscle stretch were examined after COX-1 and COX-2 inhibitors (FR-122047 and SC-236) were individually injected into the arterial blood supply of the hindlimb muscles. The results demonstrate that the stretch-evoked reflex responses in rats with HF were significantly attenuated by administration of SC-236, but not by FR-122047, i.e. renal sympathetic nerve activity and mean arterial pressure responses evoked by 0.5 kg of muscle tension were 52.3 ± 8.9% and 19 ± 1.4 mmHg, respectively, in control conditions and 26.4 ± 5.6% and 5.7 ± 1.6 mmHg (P < 0.05 versus control group) after 0.25 mg kg(-1) of SC-236. Muscle stretch-evoked renal sympathetic nerve activity and mean arterial pressure responses were 51.8 ± 8.2% and 18.7 ± 1.2 mmHg, respectively, in control conditions and 48.3 ± 5.3% and 17.5 ± 1.9 mmHg (P > 0.05 versus control group) after 1.0 mg kg(-1) of FR-122047. Accordingly, the results obtained from this study support our hypothesis that heightened COX-2 expression within the hindlimb muscles contributes to the exaggerated muscle mechanoreflex in congestive HF.

Indexed as

AnimalsBenzenesulfonamidesBlood PressureCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsHeart FailureHeart RateKidneyMaleMembrane ProteinsMuscle ContractionMuscle, SkeletalMyocardial InfarctionPiperazinesPyrazoles1-((4,5-bis(4-methoxyphenyl)-2-thiazoyl)carbonyl)-4-methylpiperazine4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamideBenzenesulfonamidesCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsMembrane ProteinsPiperazinesPtgs1 protein, ratPtgs2 protein, ratPyrazolesSulfonamidesThiazoles

Identifiers

PMID22523381
PMCPMC3606264
OpenAlexW1655003787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.